Comparing Opdivo vs Tarceva
| Opdivo (nivolumab) | Tarceva (erlotinib) |
|
|---|
| Opdivo (nivolumab) | Tarceva (erlotinib) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, colorectal cancer, and lung cancer. Fatigue, skin... View more |
Prescription only
Prescribed for Non Small Cell Lung Cancer, Pancreatic Cancer. Tarceva may also be used for purposes not listed in this medication guide. |
Related suggestions Popular comparisons
|
|||||||
| More about Opdivo (nivolumab) | More about Tarceva (erlotinib) | ||||||||
| Ratings & Reviews | |||||||||
|
Opdivo has an average rating of 5.8 out of 10 from a total of 95 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 40% reported a negative effect. |
Tarceva has an average rating of 8.5 out of 10 from a total of 42 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 10% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Opdivo side effects |
View all Tarceva side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Opdivo prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
|
N/A |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
640.8 hours |
36.2 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 594 drugs are known to interact with Opdivo:
|
A total of 305 drugs are known to interact with Tarceva:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
December 22, 2014 |
November 18, 2004 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Lumakras
Lumakras is used to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) or colorectal cancer ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat advanced non-small cell lung cancer (NSCLC) in adults that has certain ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Taxotere
Taxotere (docetaxel) treats breast cancer, lung cancer, prostate cancer and stomach cancer. Learn ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.